Merry Christmas to all .

So what is your take a good thing or bad thing for RSPI

I think that was a mic drop

Thank you

When you have gone live will you post the link , I dont have any of the social media as accounts , I will be willing to sign up . Thank you

Maybe , I also asked Jeff about that and posted that reply. Very weird when it is linked to RSPI . Time will tell

Maybe more info here I didnt sign up for it yet
https://synapse.patsnap.com/drug/8352d5be6aed4348805cfb3f7484d899

https://synapse.patsnap.com/drug/8352d5be6aed4348805cfb3f7484d899

Somebody in the Great white north or who can buy on the EM could drive this up at anytime. My understanding of the trading on EM if two matching bid and ask is there it sells, could be wrong but if true someone could put a 100 shares up for .10 and someone could match it and we would be looking good. That would be a nice sight.

Hopefully RSPI gets a great XMAS present in the form of investor funding or a play by BP. Just a matter of time now .

Hopefully the news letter he will put out isnt a rehash of already known info , but is all new and with a direction and a plan in place. GLTA

Here is what I got today from the investor group I posted awhile back and my reply . The reply he sent contains basically same info I posted awhile back that Jeff had talked about.
Hi XXXX,
Trust all is well.
I caught up with the company last week to press them on their SEC filings. Please find their response below
“With respect to getting current with our SEC filings, we would require approximately $150,000 and it would take approximately two month (subject to staff availability at our auditors) to catch up on the 31 Dec 2023 annual report and three quarterly reports. The $150K would be sufficient for us to complete timely (possibly on extension), the 31 Dec 2024 annual report.”
The company is cash-strapped, hence why it’s taking time to get their filings up to date. Would this be something you could potentially support if there was a meaningful equity component as an incentive?

Please let me know your thoughts.
Best Regards,
XXXX

Thanks I have been in talks with Jeff , I knew of the need for cash.

What I and other investors have concerns is with all the grants they have and positive results that they have released why no big invetsor or Big Pharm hasnt stepped in. The share structure that he was talking about to me just isnt enough to take more of a risk along with no gurantee they would come off EM and not return to it mid year. They could have gone a different direction than the EM , instead they went there, now they have no real way of trading to raise money. Many of us would have rather them have diluted a small amount of shares and stay on the OTC so it could have traded and build up the share price not collapse it on the EM. If we took the class shares he was talking about we would be stuck with shares that we would not be able to sell easily. I already have 15M shares at an average of .00098 and I am holding but to put in a 10k - 25k additional investment is not on my table.

Thanks for your response and have a great holiday season

Long time hope you are doing well
You served it up good with this Over 300 Million in liabilities and we are to believe a lawyer is exactly going to get what for the investors , while this clownass is out of the country. GLTAOU

Hey Doc , what does the lawyers think they will be able to recover. We all know they have no money on the books . So is this more about sending them to jail or shutting them down. What is actually recoverable ? Just asking

Nothing has changed since 2018 all hype no follow thru . Pretty sad they had a great product.

Boy does this sound just like the info we were give over the years . Sounds like the cure speech , where is Enzo the chimp he has had to be cured by now.

1606 Corp. Target for Strategic Investment Adnexus Biotechnologies Merges With Sanctum Therapeutics to Obtain Breakthrough HIV and SARS-CoV-2 Treatments
8:03 AM ET 11/12/24 | Dow Jones

SEATTLE, WA / ACCESSWIRE / November 12, 2024 / 1606 Corp. (OTC PINK:CBDW) (the "Company" or "1606"), a leader in AI technology, acquisition target Adnexus Biotechnologies Inc. is delighted to reveal the completion of a merger agreement to acquire Sanctum Therapeutics core technology assets for treating HIV and SARS-CoV-2. This merger will combine the two biotechnology companies' significant resources and expertise. The combination of resources and expertise significantly enhance the research capabilities of Adnexus's HIV and SARS-CoV-2 research.

Adnexus Biotechnologies Inc. is poised to revolutionize its HIV and infectious disease portfolio with the acquisition of Sanctum Therapeutics' leading-edge assets. This strategic merger combines Adnexus's state-of-the-art AI-driven drug discovery platform with Sanctum's innovative long-acting HIV capsid inhibitor and Adnexus's short-acting anti-HIV monoclonal antibodies. Together, these therapies offer a potent, dual-action approach that enhances treatment efficacy, reduces the risk of viral resistance, and provides a promising new option for HIV patients.

The acquisition further strengthens Adnexus's position in the rapidly growing market for HIV treatments, while also expanding its pipeline of drug candidates targeting antimicrobial-resistant infections and other infectious diseases. With Sanctum's advanced inhibitors and expertise in navigating the FDA regulatory landscape, Adnexus is uniquely positioned to accelerate the development of high-impact therapies.

Austen Lambrecht, CEO of 1606 Corp., commented, "The merger between Adnexus Biotechnologies and Sanctum Therapeutics marks a pivotal moment in the fight against HIV and other infectious diseases. By combining Adnexus's cutting-edge AI-driven drug discovery platform with Sanctum's breakthrough therapies, they are not only advancing the development of life-saving treatments but also driving forward our mission to leverage technological innovation for the betterment of global healthcare. Lambrecht continued, "This strategic partnership underscores our commitment to supporting transformative biotech advancements, and we are excited to play a role in helping bring these therapies to market for those who need them most."

This synergistic combination of resources, along with Adnexus's cutting-edge Sutra AI Drug Discovery Platform, creates a powerful foundation for continued innovation and growth, ultimately delivering significant value for patients and shareholders alike.

Adnexus has recently executed a Letter of Intent with the Company for a strategic investment by the Company for 5% of Adnexus. The LOI terminates on November 27, 2024 and has an option to extend.

About Adnexus Biotechnologies Inc.

Adnexus is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease and neurodegenerative disease research. Its proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments. For more information, please visit https://www.adnexusbiotech.com.

Hey doc where do you sign up , has that happened yet . count me in

You havent block him yet .

Yes it will be nice to get off the EM .

I can sell you 640k at .02 if you would like

Thank you for the effort. The concerns are legitimate.
In response to 1 and 2.
One of the ways we addressed the concern about the EM and possibly going back to the EM if inadequate funds were raised was by creating a security that is not dependent upon the stock to be trading for it to pay off. That was our Series I Preferred Stock that pays off if a strategic deal struck ($15mm or more in any consecutive 12 month period that need not be a calendar year) regardless if the common stock is trading or not. We recently enlarged the available Series I stock to accommodate up to $200,000 of additional investment by amending the certificate of designation with Delaware and then filing an 8-K on September 6, 2024. The way it works, and while the preferred stock is not convertible to common, we value it on a hypothetical common share basis at $0.0015/share. Then, when a strategic deal takes place that meets the criteria, the payout is at $0.02 per share. A $25K investment pays off a gross amount of ($25,000/$0.0015)x$0.02 or $333,333 for a profit of $308,333 or 12x profit. The stock does not need to be trading for the payoff to happen. I believe you have been reading our prior SEC filings, so you will be aware that we had previously sold for or used Series I to pay off liabilities for an aggregate of $245,000 and we enlarged it to accommodate up to an additional $200K. But you would have to believe we would do a strategic deal that yields $15mm in any consecutive 12 month period.
Here is the link to the 8-K itself and then the link for the actual amendment which is an exhibit to the 8-K.
https://www.sec.gov/Archives/edgar/data/849636/000149315224035221/form8-k.htm
https://www.sec.gov/Archives/edgar/data/849636/000149315224035221/ex3-1.htm
A summary of the Series I is attached that was written shortly before the actual amendment was filed in Delaware and with the SEC.
The investors we have that are interested in the Series I, are individually not of sufficient size to close. They would close if the closing was $150K or more.
In response to 3.
We have had and continue to engage with biotechs, biopharma and big pharma episodically. Eventually, we anticipate getting a deal done in one asset category or another. I personally exchanged $210,000 of accrued unpaid compensation for Series J preferred stock (other executives have exchanged as well) which is less lucrative terms than the Series I and would be harder to hit the threshold as the threshold for Series J is $20 million, $5mm higher than the threshold for Series I.
No response necessary for your point 4. It would take a lot of common which would be highly dilutive to existing shareholders like yoursel

Hello
Thanks everyone seems to have the same concerns . Here are the major and from what I am getting as feedback most will not take that risk due to the cornerns of whay the EM happened in the first place .


1) Major concern is that they invest and then 2qrt comes and their is no money and RSPI is back to the same sisutation they are in now (AKA) EM
2) If you have other investors why this hasn't been resolved
3) With everything going on , why BP or major backers stepped up for merger or buyout yet.
4) It would take atleast 50m shares for a 10m investment for them
Thank you for your time , I still hold my shares and support your research and believe you will help the millions who suffer everyday .

Not sure , Haven't called him to discuss in detail , knowing now they would need 150k est , If we were able to get 15 investors that still 10k each, I would not touch it unless I recieved 20m in shares atleast. I really dont see enough of us in here to gamble 10k until we see something moving positively in the right direction. IMO Any one is welcome to reach out to Jeff he is very responsive when I have . GLTA

Sorry should be a reply to Dyno Followup to the two questions I justed asked based off some concerns

One can use the alternative of filing unaudited, but it involves getting a legal opinion on disclosures. That involves an opinion committee and all in, that would cost approximately the same as the audit plus the delayed 10-Qs and take the same amount of time. And ultimately, we would need to get the audit and Qs done anyway. We checked with our counsel quite a while ago, when the auditor costs would have been lower (not as many Qs were behind schedule at that time) before coming to that conclusion.

You’re right to be concerned about the next upcoming K due in March. If w wanted to ensure that, we’d need more line $150k. I have other investors who would join if we could reduce the risk of that problem

All good replies , I have sent another round of questions based on your feedback and concerns as it matches mine

Okay , ballpark what would it take , so I can talk with the others , some had suggested it might be as high as 110k

Everybody would need to be an accredited investor. Around $100k would be a good estimate.

Also a little off topic but if money is an issue with the audits , could some of investors pay what it would take in exchange for more shares could that be an option
Thanks and enjoy your weekend .

Yes. That would be an option. I’d be happy to speak with you by phone about that.

A little update
I promised that I would get to you this week and although the information I have is sparse, this is what I can tell you.


I dug through our digital archives and came up with some information about CX 929.



This information is really old, some of it going back to a time before I was involved with RespireRx (when it was then known as Cortex). I have been involved with RespireRx for 11.5 years.



I can’t say for sure if the patents on the compound still exist. Patent life in the US is ~20 years. Even if they have not expired, the likelihood of being able to develop drug candidate before the patents expire is pretty slim. That is not to say that is the only criteria for developing a drug.

What I can discern is that it seems to have been studied in several rat studies of cognition.

In speaking with my colleagues, there may be difficulties with its pharmacology that may be the reason why development was not continued.

I’ll look deeper, but what I’ve seen so far is not promising. There seem to be more promising molecules in our portfolio – CX 1739, CX 717, CX 1942 and maybe others.

I hope this information, while it may be disappointing, is helpful.

Hopefully not a repeat of ENZC , I dont think it is. I see the first QRT of 2025 start to move for the better . GLTA

Latest update on a few things I asked about today
Jeff Margolis

Tue, Oct 29 at 8:54 PM

I’ve been remiss on CX 929. I’ll try to get something to you by end of the week.

We’d like to get off the EM as soon as possible, but I can’t put a time frame on it.

DOD grant is moving slowly but moving.

Australia also going slowly, but hope to pick up the pace soon.

Patents move on their own schedule. Nothing holding anything up there.

Several irons in the fire, as is always the case.

Thank you.

Sincerely,

Jeff

Never said they owned it , was just showing who made it , i cant find a patent issued , I would say he has sometype of protection or licening deal.

Dizocilpine and AMPA were both purchased from Research Biochemicals; NBQX from Tocris Neuramin (Bristol, U.K.) Cyclothiazide and the 1-(aminophenyl)-4-methyl-7,8-methylendioxy-5H-2,3-benzodiazepine (GYKI 52466) were a gift from Lilly Research Laboratories. IDRA-21 was kindly synthesized by A. Kozikowski (Georgetown University, Washington, DC) and found chemically pure by gas chromatographic mass fragmentographic analyses). Fura-2, and SBFI were obtained from Molecular Probes. All other drugs were purchased from Sigma. Stock solutions of IDRA-21 and cyclothiazide were prepared in dimethyl sulfoxide at concentrations of 100 mM; dilutions were made before every experiment. The highest concentration of dimethyl sulfoxide was 0.1%. We made sure that this concentration of dimethyl sulfoxide did not affect the parameters to be measured in the cells.

Here is a link that talks about all their claims along with a link to hicks interview about the white paper
https://www.biospace.com/enzolytics-announces-a-comprehensive-therapeutic-protocol-for-production-of-monoclonal-antibodies-to-address-ongoing-and-future-pandemics

They have accounts in Canada and other countries outside the US

closing 0.0025 we go to the moon, in 2025 we go to 0.2 $

I hear you , if I was Hicks I would call him out , but we all know the Doctor or Charles will not make any statements now.

I haven't seen anything related to Samsung posted , by chance have you reached out to Hicks to see what he thinks about all this. Alot of info was talked about in thoses interviews which could help show what they were stating and who they said were involved with ENZC. He to may have been mislead or was in on it, either wayn he and others have egg on their face GLTA

I wonder if Samsung campus office would tell us if the statement is true.

That day will be coming for all of us GLTA

No about the compound I asked about 3 weeks ago, he was sent 8 pages by his staffers about it and he is summarizing thoses

Just an update sorry I didn't post right away will followup when I get new info . Have a great day GLTA


Jeff Margolis

From:
jmargolis@respirerx.com
To:
xxxx

Thu, Oct 17 at 3:57 PM

Yes. I have been sent 8 papers and we have some summarizing. Sincerely, Jeff
Sent from my iPhone

Show original message

Hello Doc Wednesday was the deadline correct? What is the next step you are planning.

No problem here so you must know everything as an investor sorry that a question upset you. Have a great weekend. Go back to IGPK and hope they pump it to make money off a website from China Owned goverment run companies you are waiting for a name change last I checked how long has it been 5 months now? just asking for a freind nah I an asking for me. Now go and have a great weekend ,when RSPI lands at .10 and from there out every .10 cent is a 1.5 million winfall , I will ask what questions I would like at this point. GLTA